mRNA is synthesized in the nucleus with the use of a template made up of a DNA nucleotide sequence. This process is referred to as transcription. It involves various stages such as initiation, elongation, editing, and termination. The raw materials required are bacteriophage, DNA template, RNA polymerase, and NTPs. The amino acids required for transcription are uracil, cytosine, adenine, and guanine. Following are the steps of mRNA synthesis:
mRNA synthesis has a wide range of applications in the manufacturing of therapeutics, vaccine development, and drug discovery. RNA–based vaccines have higher efficiency, better immunogenicity, and require short production time. Moreover, the manufacturing cost of the synthesis is also low. For instance, in November 2020, Pfizer, Inc. and BioNtech, Inc. launched a vaccine BNT162b2 against the SARS-CoV-2 COVID-19 virus. The advancements in medical technologies propel the market. Along with this, improvement in the service quality through novel product launches by the major pharmaceutical companies drives the RNA synthesis raw material market.
The demand for gene therapies has increased due to the increasing prevalence of cancer and chronic diseases. The rise in awareness among people and healthcare workers for the early diagnosis and treatment of chronic disorders has also increased. Due to the approach of delivering products with better quality and efficacy, the key players in the market have a higher demand for quality raw materials for efficient mRNA synthesis. This is required for developing efficient and safe drug products, vaccines, and therapeutics. Moreover, the collaborations, mergers and strategic alliances between the key players to enhance the raw material supply propels the market. For instance, in September 2022, TriLink Bio Technologies announced its expansion in delivering the GMP-grade product N1-Methyl Pseudouridine-5'-Triphosphate. It is the modified form of the NTP required for the synthesis of mRNA. This new product launch enhances the company's GMP capabilities and analytical testing department.
The market is segmented into type, application, end-use, and region. The type segment is divided into capping analogs, DNA template, nucleotides and polymerase. The application segment is classified into therapeutic production, vaccine production, and drug discovery. The end user segment is classified into biotechnology companies, pharmaceutical companies, research and academic institutes, and others. The region segment is classified into North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
Based on the regional analysis, North America dominates the global mRNA synthesis raw materials market. The availability of the key market players for the supply of raw materials and increased research funding drives the market. Moreover, North America also has a large number of clinical trial activities which boosts the growing market. Europe also holds a significant stake due to the increasing need and awareness for mRNA-based vaccines and therapeutics for treating chronic and genetic disorders.
Major companies operating in the mRNA synthesis raw materials market include Thermo Fisher Scientific, Inc., Jena Bioscience, Sartorius AG, Cytiva, Moderna, Inc., H3 Biomedicine Inc., Kernal Biologics, Ziphius Therapeutics, Merck KGaA, miRagen Therapeutics, Inc., Skyhawk Therapeutics, Inc., Tiba Biotechnology, CureVac, Translate Bio, Sigma Aldrich, TriLink Bio Technologies among others.
Market Segmentation
By Type
By Application
By End-user
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on MRNA Synthesis Raw Materials Market
5.1. COVID-19 Landscape: MRNA Synthesis Raw Materials Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global MRNA Synthesis Raw Materials Market, By Type
8.1. MRNA Synthesis Raw Materials Market, by Type, 2022-2030
8.1.1 Capping Enzymes
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. DNA template
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Nucleotides
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Polymerase
8.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global MRNA Synthesis Raw Materials Market, By Application
9.1. MRNA Synthesis Raw Materials Market, by Application, 2022-2030
9.1.1. Therapeutics Production
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Vaccine Production
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Drug Discovery
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global MRNA Synthesis Raw Materials Market, By End-user
10.1. MRNA Synthesis Raw Materials Market, by End-user, 2022-2030
10.1.1. Biotechnology Companies
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Pharmaceutical Companies
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Research and Academic Institutes
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global MRNA Synthesis Raw Materials Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Type (2017-2030)
11.1.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.3. Market Revenue and Forecast, by End-user (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Type (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.4.3. Market Revenue and Forecast, by End-user (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.5.3. Market Revenue and Forecast, by End-user (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Type (2017-2030)
11.2.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.3. Market Revenue and Forecast, by End-user (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Type (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.4.3. Market Revenue and Forecast, by End-user (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.5.3. Market Revenue and Forecast, by End-user (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Type (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.6.3. Market Revenue and Forecast, by End-user (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Type (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.7.3. Market Revenue and Forecast, by End-user (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Type (2017-2030)
11.3.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.3. Market Revenue and Forecast, by End-user (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Type (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.4.3. Market Revenue and Forecast, by End-user (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.5.3. Market Revenue and Forecast, by End-user (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Type (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.6.3. Market Revenue and Forecast, by End-user (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Type (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.7.3. Market Revenue and Forecast, by End-user (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Type (2017-2030)
11.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.3. Market Revenue and Forecast, by End-user (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Type (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.4.3. Market Revenue and Forecast, by End-user (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.5.3. Market Revenue and Forecast, by End-user (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Type (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.6.3. Market Revenue and Forecast, by End-user (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Type (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.7.3. Market Revenue and Forecast, by End-user (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.3. Market Revenue and Forecast, by End-user (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Type (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.4.3. Market Revenue and Forecast, by End-user (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.5.3. Market Revenue and Forecast, by End-user (2017-2030)
Chapter 12. Company Profiles
12.1. Thermo Fisher Scientific, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Jena Bioscience
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Sartorius AG
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Cytiva
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Moderna, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. H3 Biomedicine Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Kernal Biologics
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Ziphius Therapeutics
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Merck KGaA
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. miRagen Therapeutics, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms